Caspase-mediated cleavage and dissipation of Mcl-1 may be a highly likely scenario in CLL cells from patients treated with ibrutinib and venetoclax therapy, however, such postulates need to be tested. This evidence concerns the gene MCL1 and B-cell chronic lymphocytic leukemia.